Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
10 papers
Recent·Most cited
E. Kon, Y. Levy, U. Elia, H. Cohen, I. Halevy, M. Aftalion, A. Ezra, E. Bar-Haim, G. S. Naidu, Y. Diesendruck, S. Rotem, N. Ad-El, M. Goldsmith, E. Mamroud, D. Peer, O. Cohen
This study develops an mRNA-LNP vaccine against Yersinia pestis, showing it provides full protection against infection in animals.
bioRxiv · Aug 7, 2022 · PreprintMicrobiology
O. Perlman, H. Ito, K. Herz, N. Shono, H. Nakashima, M. Zaiss, E. A. Chiocca, O. Cohen, M. S. Rosen, C. T. Farrar
This paper introduces an AI-enhanced molecular MRI technique to detect apoptosis in oncolytic virotherapy, showing early detection of apoptotic response in a glioblastoma model and clinical validation in a human subject.
Nature Biomedical Engineering · Nov 11, 2021Peer-reviewedBiophysics
M. Israeli, Y. Finkel, Y. Yahalom-Rone, N. Paran, T. Chitlaru, O. Israeli, I. Cohen-Gihon, M. Aftalion, R. Falach, U. Elia, I. Nemet, L. Kliker, M. Mandelboim, A. Beth-Din, T. Israely, , A. Bercovich-Kinori
This study uses CRISPR screens to identify host factors critical for SARS-CoV-2 infection, finding GATA6 as a key modulator of ACE2 expression and viral entry.
bioRxiv · Jul 19, 2021 · PreprintMicrobiology
U. Elia, S. Rotem, E. Bar-Haim, S. Ramishetti, G. S. Naidu, D. Gur, M. Aftalion, M. Israeli, A. Bercovich-Kinori, R. Alcalay, E. Makdasi, T. Chitlaru, R. Rosenfeld, T. Israely, S. Melamed, , O. Cohen
This study evaluates an mRNA vaccine against SARS-CoV-2 in hACE2 transgenic mice, showing 70% protection against a lethal infection.
bioRxiv · Mar 29, 2021Microbiology
K. Pelka, M. Hofree, J. Chen, S. Sarkizova, J. D. Pirl, V. Jorgji, A. Bejnood, D. Dionne, W. H. Ge, K. H. Xu, S. X. Chao, D. R. Zollinger, D. J. Lieb, J. W. Reeves, C. A. Fuhrman, , J
The paper identifies immune hubs in colorectal cancer by analyzing transcriptional and spatial patterns in MMRd and MMRp tumors.
bioRxiv · Jan 30, 2021 · PreprintCancer Biology
U. Elia, R. Srinivas, N. Dammes, E. Bar-Haim, G. S. Naidu, E. Makdasi, O. Cohen, D. Peer
This study designs an mRNA vaccine targeting SARS-CoV-2 RBD using novel ionizable lipids, showing strong immune responses in mice.
bioRxiv · Oct 15, 2020Immunology
S. A. Wander, O. Cohen, X. Gong, G. N. Johnson, J. Buendia-Buendia, M. R. Lloyd, D. Kim, F. Luo, P. Mao, K. Helvie, K. J. Kowalski, U. Nayar, A. G. Waks, S. Parsons, R. Martinez, , N. Wagle
The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.
bioRxiv · Nov 28, 2019Cancer Biology
A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, , N. Wagle
This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.
bioRxiv · Nov 10, 2019Cancer Biology
P. Mao, O. Cohen, K. J. Kowalski, J. G. Kusiel, J. E. Buendia-Buendia, M. S. Cuoco, P. Exman, S. A. Wander, A. G. Waks, U. Nayar, J. Chung, S. Freeman, O. Rozenblatt-Rosen, V. A. Miller, F. Federica Piccioni, , N. Wagle
This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.
bioRxiv · Oct 7, 2019Cancer Biology
L. Jerby, C. Neftel, M. E. Shore, M. J. McBride, B. Haas, B. Izar, H. R. Weissman, A. Volorio, G. Boulay, L. Cironi, A. R. Richman, L. C. Broye, J. M. Gurski, C. C. Luo, R. Mylvaganam, , A. Regev
The paper profiles synovial sarcoma tumors to show that the SS18-SSX fusion drives oncogenic programs, which are repressed by immune cells and can be targeted with HDAC and CDK4/6 inhibitors.
bioRxiv · Aug 4, 2019 · PreprintCancer Biology